FDA greenlights self-collection of vaginal samples for cervical cancer screening

Instead of a traditional speculum-involved pelvic exam to screen for cervical cancer, the US Food and Drug Administration has given the go-ahead for patients to have the option to collect their own vaginal samples for screening in a health care setting, such as at their doctor’s office, an urgent care or even a mobile clinic.

“Almost all cervical cancers are caused by persistent infection with certain types of HPV,” Dr. Karen E. Knudsen, CEO of the American Cancer Society, said in a statement Wednesday. “Self-collection can expand access to screening and reduces barriers, which will give more people the opportunity to detect, treat, and ultimately survive cancer.”

May 15, 2024 - CNN

Previous
Previous

ASCO, ACS Collaborate to Create Most Comprehensive Online Sources of Credible Cancer Info

Next
Next

Cancer patients often face medical debt, even with insurance